Skip to main content
SpringerLink
Log in

Will the promise of the COX-2 selective NSAIDs come to fruition?

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 2000 Jun; 59 (6): 1207–16

    Article  PubMed  CAS  Google Scholar 

  2. Hawkey CJ. Non steroidal anti-inflammatory drugs and peptic ulcers: facts and figures multiply, but do they add up? BMJ 1990; 300: 278–84

    Article  PubMed  CAS  Google Scholar 

  3. Hawkey CJ, Hudson N. Mucosal injury caused by drugs, chemicals and stress. In: Haubrich WS, Schaffner F, Berck JE, editors. Bockus gastroenterology 5 (2). Philadelphia (PA): WB Saunders, 1994: 656–99

    Google Scholar 

  4. Pairet M, Van Ryn J, Mauz A, et al. Differential inhibition of COX-1 and COX-2 by NSAIDs: a summary of results obtained using various test systems. In: Vane J, Botting J, editors. Selective COX-2 inhibitors: pharmacology, clinical effects and therapeutic potential. London: Kluwer Academic Publishers, 1997; 3: 27–46

    Google Scholar 

  5. Davies NM, McLachlan AJ. Propriétés et spécificités de la nabumétone. Drugs 2000; 59 Spec. Issue 1: 25–33

    Article  PubMed  CAS  Google Scholar 

  6. Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993 Mar 25; 268: 6610–4

    PubMed  CAS  Google Scholar 

  7. Laneuville O, Breuer DK, Dewitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271: 927–34

    PubMed  CAS  Google Scholar 

  8. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271: 1705–12

    PubMed  CAS  Google Scholar 

  9. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999 June 22; 96 (13): 7563–8

    Article  PubMed  CAS  Google Scholar 

  10. Gerson GC. Worldwide safety experience with nabumetone. J Rheumatol 1992; 19 Suppl. 36: 48–56

    Google Scholar 

  11. Richardson C, Emery P. The clinical implications of inhibition of the inducible form of cyclo-oxygenase. Drug Saf 1996 Oct; 15 (4): 249–60

    Article  PubMed  CAS  Google Scholar 

  12. Patoia I, Santucci I, Furno P, et al. A four-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5mg, meloxicam 15mg, piroxicam 20mg and placebo by means of faecal blood loss, endoscopy and symptoms evaluation in healthy volunteers. Br J Rheumatol 1996; 35: 61–7

    Article  PubMed  CAS  Google Scholar 

  13. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of the COX-2 inhibitor, meloxicam, in osteoarthritis patients: the meloxicam large scale international study safety assessment (MELISSA). Br J Rheumatol 1998; 37: 937–45

    Article  PubMed  CAS  Google Scholar 

  14. Dequeker J, Hawkey C, Kahan A, et al. on behalf of the SELECT Study Group. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946–51

    Article  PubMed  CAS  Google Scholar 

  15. Davis R, Brogden RN. Nimesulide: an update on its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431–54

    Article  PubMed  CAS  Google Scholar 

  16. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalisation for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158(1): 33–9

    Article  PubMed  CAS  Google Scholar 

  17. Balfour JA, Buckley MMT. Etodolac: a reappraisal of its pharmacology and therapeutic use in rheumatic disease and pain states. Drugs 1991; 42: 274–99

    Article  PubMed  CAS  Google Scholar 

  18. Russell RI. Endoscopic evaluation of etodolac and naproxen and their relative effects on gastric and duodenal prostaglandins. Rheumatol Int 1990; 10: 17–21

    Article  PubMed  Google Scholar 

  19. Matheson AJ, Figgitt DP. Rofecoxib: a review of its use in the management of osteoarthritis and acute pain. Drugs 2001 May; 61 (6): 833–865

    Article  PubMed  CAS  Google Scholar 

  20. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999 Nov 24; 282 (20): 1929–33

    Article  PubMed  CAS  Google Scholar 

  21. Watson DJ, Harper SE, Zhao PL, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000 Oct 23: 160 (19): 2998–3003

    Article  PubMed  CAS  Google Scholar 

  22. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000 Nov 23; 343 (21): 1520–8

    Article  PubMed  CAS  Google Scholar 

  23. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000 Apr; 59 (4): 957–80

    Article  PubMed  CAS  Google Scholar 

  24. GD Searle and Company. Celecoxib prescribing information. Skokie, Illinois, 1999, Dec 23

  25. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921–8

    Article  PubMed  CAS  Google Scholar 

  26. Singh G, Ramey DR, Triadafilopoulos G. Early experience with selective COX-2 inhibitors: safety profile in over 340,000 patient-years of use [abstract]. Arthritis Rheumatism 1999: 296

  27. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Jama 2000 Sep 13; 284 (10): 1247–55

    Article  PubMed  CAS  Google Scholar 

  28. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamices of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000 Mar; 38 (3): 225–42

    Article  PubMed  CAS  Google Scholar 

  29. Whelton A, Maurath CJ, Verberg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase (COX)-2 inhibitor. Am J Ther 2000 May; 7: 159–75

    Article  PubMed  CAS  Google Scholar 

  30. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000 Jul 4; 133(1): 1–9

    PubMed  CAS  Google Scholar 

  31. Role of proton pump inhibitors in the prevention of NSAID-induced ulcers now emerging. Drug Ther Perspect 2000 Dec 4; 16 (12): 6-9

  32. Wallace JL. Non steroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000–16

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Will the promise of the COX-2 selective NSAIDs come to fruition?. Drugs Ther. Perspect 17, 6–10 (2001). https://doi.org/10.2165/00042310-200117110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117110-00002

Keywords

Search

Navigation